dup 105 has been researched along with dup 721 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brittelli, DR; Carlson, RK; Corless, PF; Gregory, WA; Kezar, HS; Miller, SJ; Park, CH; Rajagopalan, P; Wang, CL; Wuonola, MA | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
1 review(s) available for dup 105 and dup 721
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
1 other study(ies) available for dup 105 and dup 721
| Article | Year |
|---|---|
Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group.
Topics: Anti-Bacterial Agents; Chemical Phenomena; Chemistry; Enterococcus faecalis; Microbial Sensitivity Tests; Oxazoles; Staphylococcus aureus; Structure-Activity Relationship | 1990 |